Ide-cel or Standard Regimens in Relapsed and Refractory Multiple ...
Feb 10, 2023 · Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, previously led to deep, durable responses in patients …
Ide-cel in Multiple Myeloma Post-Transplant: Insights From Garfall
Mar 5, 2025 · 0:10 | So, this is a clinical trial that tests the use of ide-cel, an anti-BCMA CAR T-cell product, to improve response for patients who have been through the standard intensive …
The Differences between Ide-Cel and Cilta-Cel in Relapsed …
Nov 5, 2024 · Introduction: The two commercially available BCMA-directed CAR T cell therapies idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) have revolutionized …
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Feb 24, 2021 · Idecabtagene vicleucel (ide-cel, also called bb2121), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, has shown clinical activity …
ABECMA (idecabtagene vicleucel) - International Myeloma …
Abecma® (idecabtagene vicleucel, “ide-cel”) is the first-in-class B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell immunotherapy approved by the U.S. Food …
Ide-cel, a BCMA-directed CAR-T cell therapy, shows favorable risk ...
Mar 13, 2021 · Updated results from a phase 1 study (CRB-401) of idecabtagene vicleucel (ide-cel, bb2121), an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell …
Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for ... - PubMed
As the first CAR T-cell product approved for myeloma, ide-cel is poised to become a practice-changing treatment option. This first-in-class therapeutic offers hope for more durable …
FDA Approves Ide-Cel for Relapsed/Refractory Multiple Myeloma
Mar 27, 2021 · The FDA has approved idecabtagene vicleucel (ide-cel; formerly bb2121; Abecma) for the treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more …
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: …
Jan 9, 2023 · Idecabtagene vicleucel (ide-cel) is an autologous B-cell maturation antigen–directed chimeric antigen receptor T-cell therapy approved for relapsed/refractory multiple myeloma …
Cilta-Cel vs Ide-Cel in Rel/Ref MM - Cancer Therapy Advisor
Mar 4, 2025 · Ultimately, 350 patients received ide-cel, and 236 received cilta-cel. The median follow-up was 12.6 months for the ide-cel group and 13.0 months for the cilta-cel group.